In vivo effects of the monoamine oxidase inhibitors Ro 41-1049 and Ro 19-6327 on the production and fate of renal dopamine
Ro 41-1049 (2 mg/kg), but not Ro 19-6327 (2 mg/kg), was found to reduce (70% to 93% decrease) DOPAC tissue levels in the renal cortex, outer and inner medulla and, to a similar extent, DOPAC concentrations in plasma. This inhibitory effect was, however, not accompained by an increased accumulation of newly-formed dopamine. The results presented show that type A monoamine oxidase is the predominant form of the enzyme involved in the metabolism of renal dopamine and some of the amine which escapes deamination might leave the kidney through the renal vein in the intact from.
KeywordsMonoamine Oxidase Renal Vein Renal Tissue Renal Medulla Outer Medulla
Unable to display preview. Download preview PDF.
- Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Marti JS, Muggli-Maniglio D, Kyburz E, Imhof R (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm [Suppl] 29: 279–292.Google Scholar
- Pestana M, Soares-da-Silva P (1992) Cell outward transport of renal dopamine and the involvement of type A and B monoamine oxidase. J Am Soc Nephrol 3: 833.Google Scholar
- Youdim MBH, Finberg JPM, Tipton KF (1988) Monoamine oxidase. In: Trendelenburg, U, Weiner N (eds) Catecholamines, vol I. Springer, Berlin Heidelberg New York Tokyo, pp 119–192.Google Scholar